logo-loader

Vectura eyes milestone payment as inhaler approval moves a step closer

Published: 07:29 01 May 2020 BST

Vectura Group PLC -

Vectura Group PLC (LON:VEC) has drawn attention to a recommendation relating to the use of one of the company’s asthma treatment formulations in Europe.

In a statement, the company noted that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Novartis's Enerzair Breezhaler (QVM149).

Enerzair Breezhaler, which uses a formulation devised and licensed by Vectura, is a maintenance treatment for uncontrolled asthma in adult patients. Uncontrolled patients are those whose asthma is not adequately controlled with a maintenance combination of a long-acting beta2 agonist (LABA) and a high dose of an inhaled corticosteroid (ICS) who experienced one or more asthma exacerbations in the previous year.

A final decision from the European Commission regarding the grant of a marketing authorisation is expected to be received roughly two months after a CHMP opinion. Upon European regulatory approval, Vectura will be eligible to receive a US$5.0 million milestone and thereafter a low-single-digit royalty on net sales.

FTSE rises ahead of Easter weekend, JD Sport gains on upbeat outlook -...

The FTSE 100 gained on the final morning of this shortened Easter trading week. Festive cheer was limited though, as Thames Water confirmed shareholders would not provide it with a £500 million rescue package, prompting speculation over the London supplier’s future. On a more positive...

23 minutes ago